G. L. Beretta, L. Gatti, V. Benedetti, P. Perego and F. Zunino Pages 856 - 868 ( 13 )
Small molecules targeting p53 represent an emerging group of potentially useful agents for the improvement of antitumor therapy. These modulators include agents that activate wild-type p53 or reactivate mutant p53 and inhibitors of p53 functions. Preclinical evidences support the interest of combination strategies with conventional antitumor agents.
p53, nutlins, pifithrins, histone deacetylase inhibitors, ubiquitin ligase inhibitors, apoptosis, cancer cells, drug combination
Fondazione IRCCS Istituto Nazionale Tumori, ViaVenezian 1, 20133Milan, Italy.